• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alvotech - Ordinary Shares (NQ: ALVO )

    14.57 +0.35 (+2.46%)
    Streaming Delayed Price Updated: 11:43 AM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 103,531
    Open 14.67
    Bid (Size) 14.54 (17)
    Ask (Size) 14.60 (4)
    Prev. Close 14.22
    Today's Range 14.46 - 14.76
    52wk Range 6.700 - 18.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
    From Alvotech
    Via GlobeNewswire

    Performance

    YTD
    +28.26%
    +28.26%
    1 Month
    +16.84%
    +16.84%
    3 Month
    -4.46%
    -4.46%
    6 Month
    +67.47%
    +67.47%
    1 Year
    +45.26%
    +45.26%

    More News

    Read More
    Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
    From Alvotech
    Via GlobeNewswire
    ALVO Stock Earnings: Alvotech Reported Results for Q4 2023
    Via InvestorPlace
    Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
    From Alvotech
    Via GlobeNewswire
    Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Alvotech's Earnings: A Preview
    Via Benzinga
    Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
    From Alvotech
    Via GlobeNewswire
    Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
    From Alvotech
    Via GlobeNewswire
    Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Alvotech Announces Increase in Number of Own Shares
    From Alvotech
    Via GlobeNewswire
    Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
    From Alvotech
    Via GlobeNewswire
    Earnings Scheduled For March 20, 2024
    Via Benzinga
    Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
    From Alvotech
    Via GlobeNewswire
    Alvotech Appoints Interim Chief Quality Officer
    From Alvotech
    Via GlobeNewswire
    TEVA Stock Pops 4% as Teva Receives FDA Approval
    Via InvestorPlace
    Exposures Product Safety
    Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
    Via Benzinga
    Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
    From Alvotech
    Via GlobeNewswire
    Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
    From Alvotech
    Via GlobeNewswire
    Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
    From Alvotech
    Via GlobeNewswire
    American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
    From Alvotech
    Via GlobeNewswire
    3 mid-caps under $20 that Wall Street loves
    Via MarketBeat
    Topics Artificial Intelligence Economy
    Exposures Artificial Intelligence Interest Rates
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.